IQVIA Standardizes on Veeva Clinical Suite, Expanding Enterprise Deal
VEEV has more than doubled off its 52-week low of $148.05.
Summary
IQVIA has selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard applications across its clinical studies, extending the existing EDC partnership. This deepens Veeva's relationship with one of the largest CROs and signals broader seat expansion and multi-year revenue durability. The deal also includes resale of Veeva solutions through IQVIA, which could accelerate adoption among new sponsors. No financial terms were disclosed, but the enterprise-wide standardization is a material positive for Veeva's clinical suite strategy. This follows Veeva's strong Q2 FY2027 results and recent insider selling by former President Thomas Schwenger.
At the time of this announcement, VEEV was trading at $299.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $47.9B. The 52-week trading range was $148.05 to $302.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.